Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition

Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition

Background: Immune checkpoint inhibitors (ICI) are increasingly the mainstay of oncology treatment. Immune-related adverse events (irAEs) from ICI therapy differ from cytotoxic adverse events. Cutaneous irAEs are one of the most common irAEs and require careful attention to optimize the quality of l...

Full description

Bibliographic Details
Main Authors:	Sze Wah Samuel Chan, Rahul Shukla, Jennifer Ramsay, Elaine McWhirter, Paul Barnfield, Rosalyn A. Juergens
Format:	Article
Language:	English
Published:	MDPI AG 2023-04-01
Series:	Current Oncology
Subjects:	anti-PD-1 inhibitor immune-related adverse events cutaneous immune-related adverse events squamous cell carcinoma immune checkpoint inhibitor pembrolizumab
Online Access:	https://www.mdpi.com/1718-7729/30/5/342

Similar Items

Immune Checkpoint Inhibitor-Induced Gastroduodenitis: Recurrence after Rechallenge with Pembrolizumab
by: Catarina O’Neill, et al.
Published: (2021-04-01)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
by: I. Puzanov, et al.
Published: (2017-11-01)

Overview and management of toxicities of immune checkpoint-blocking drugs
by: Economopoulou Panagiota, et al.
Published: (2016-03-01)

Immune Checkpoint Inhibitor Associated Autoimmune Encephalitis, Rare and Novel Topic of Neuroimmunology: A Case Report and Review of the Literature
by: Yining Gao, et al.
Published: (2022-06-01)

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report
by: Maria Anna Siciliano, et al.
Published: (2020-10-01)

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)
by: M. Yu. Fedyanin, et al.
Published: (2023-06-01)

Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review
by: Nabil E. Omar, et al.
Published: (2020-10-01)

Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study
by: Yizhang Hu, et al.
Published: (2022-09-01)

Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study
by: Nadia Guezour, et al.
Published: (2022-08-01)

Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
by: Vivek Kumar, et al.
Published: (2017-05-01)

The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer
by: Courtney H. Coschi, et al.
Published: (2021-11-01)

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database
by: Quentin Scanvion, et al.
Published: (2020-01-01)

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report
by: Camille M. Powers, et al.
Published: (2024-12-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
by: Yue Li, et al.
Published: (2020-04-01)

Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced “Eosinophilic Fasciitis-Like” Case and a Review of the Literature
by: Christina Salamaliki, et al.
Published: (2020-10-01)

A case of severe acute hemorrhagic duodenitis after administration of immune checkpoint inhibitor
by: Keita Saito, et al.
Published: (2022-04-01)

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy
by: Terufumi Kubo, et al.
Published: (2021-09-01)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
by: Junling Zhuang, et al.
Published: (2020-03-01)

Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events
by: Junling ZHUANG, et al.
Published: (2019-10-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors
by: Yue LI, et al.
Published: (2019-10-01)

Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: LI Ying, et al.
Published: (2021-04-01)

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
by: Benjamin C. Park, et al.
Published: (2023-12-01)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
by: Roser Calvo
Published: (2019-04-01)

Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews
by: WANG Xue, et al.
Published: (2020-06-01)

Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review
by: Marion Allouchery, et al.
Published: (2022-02-01)

Mycophenolate mofetil for immune checkpoint inhibitor‐related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review
by: Masayuki Ueno, et al.
Published: (2022-09-01)

Very Delayed Acute Hepatitis after Pembrolizumab Therapy for Advanced Malignancy: How Long Should We Watch?
by: Timothy Phan, et al.
Published: (2021-02-01)

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
by: Hideki Terai, MD, et al.
Published: (2022-11-01)

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
by: Abdulaali R. Almutairi, et al.
Published: (2020-02-01)

A case of relapsing aseptic meningitis under excellent tumor response to pembrolizumab in microsatellite instability-high recurrent endometrial cancer
by: Daito Noguchi, et al.
Published: (2021-11-01)

Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis
by: Mike Nguyen, et al.
Published: (2019-09-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspectiveResearch in context
by: Paul Gougis, et al.
Published: (2024-04-01)

Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials
by: Yang Ge, et al.
Published: (2021-07-01)

Imaging assessment of toxicity related to immune checkpoint inhibitors
by: Antonia M. Berz, et al.
Published: (2023-02-01)

Immune checkpoint inhibitor-related acral vasculitis
by: Thibault Comont, et al.
Published: (2018-11-01)

IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS
by: Ioana Cretu, et al.
Published: (2018-12-01)

Immune checkpoint inhibitor‐mediated psoriasis treated with biologics
by: Pei Ming Yeo, et al.
Published: (2023-06-01)

Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms
by: Rishi Rikhi, et al.
Published: (2021-08-01)

Protracted complete response after limited checkpoint inhibitor dosing: A case report
by: Quinne Sember, et al.
Published: (2023-10-01)